Exercise |
Exercise can slow diabetic peripheral neuropathy |
http://linkinghub.elsevie... |
Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes |
http://care.diabetesjourn... |
How short-term diet and exercise effect overweight children |
http://linkinghub.elsevie... |
Nutrition |
New study published in diabetes care shows that supplementation with chromium picolinate significantly improves glycemic control and attenuates weight gain |
http://linkinghub.elsevie... |
High levels of certain pollutants in the body have been associated with an increased risk for diabetes. Further studies are needed to confirm the results |
http://care.diabetesjourn... |
Metabolic effects of spices, teas, and caffeine |
http://blogs.healthcentra... |
Diabetes prevention |
New study seeks to lower diabetes risk in youth |
see full article in our parents & children and medical news section. |
http://www.eurekalert.org... |
High levels of certain pollutants in the body have been associated with an increased risk for diabetes. Further studies are needed to confirm the results |
http://care.diabetesjourn... |
The national diabetes education program has designed a national awareness campaign to target people at risk for type 2 diabetes. |
The campaign will create awareness that type 2 diabetes can be prevented through modest lifestyle changes and losing about 5 to 7 percent of body weight. |
http://www.ndep.nih.gov/c... |
Children's health |
New study seeks to lower diabetes risk in youth |
See full article in our parents & children and medical news section. |
http://www.eurekalert.org... |
How short-term diet and exercise effect overweight children |
http://linkinghub.elsevie... |
Diabetes Medications |
Refrigerating insulin and Byetta |
http://blogs.healthcentra... |
Byetta (medication for t2 diabetes from Amylin pharmaceuticals and illy) is back |
http://blogs.healthcentra... |
Controlling nausea on Byetta |
http://blogs.healthcentra... |
Research Updates Products & Trials |
Emisphere Completes Enrollment for Phase Ii Oral Insulin Clinical Trial |
No Safety Concerns Raised to Date on Oral Insulin Product Company Receives Approval to Expand Study from 120 to 140 Patients Emisphere provides update on use of the eligen(r) technology to enhance pulmonary delivery of proteins, including insulin Emisphere has issued patents with claims directed to pulmonary delivery of peptides Pre-clinical data demonstrates high bioavailability Favorable safety profile Pulmonary delivery of insulin in combination with Emisphere carrier reduces the up-regulation of immune response genes Second generation inhaled insulin formulations demonstrating promise in clinical studies |
http://www.emisphere.com/... |
Diabetes Medications |
Intensive insulin therapy reduces LDL (low-density lipoprotein) particles in patients with type 2 diabetes mellitus |
http://linkinghub.elsevie... |
Cardiovascular /controlling Blood Sugars |
Effects of lifestyle modification and the influence on cardiovascular disease of type 2 diabetes |
http://linkinghub.elsevie... |
Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies |
http://linkinghub.elsevie... |
Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes |
http://care.diabetesjourn... |
Continuous Glucose Monitoring |
Dexcom receives FDA approval for dm™ consumer data manager |
http://www.dexcom.com/htm... |
Research Updates Products & Trials |
Renal and cardiovascular complications of type 2 diabetes mellitus, can be hereditary |
http://hyper.ahajournals.... |
Diamyd medical is focused on developing treatments for diabetes, both type 1 and type 2, via gad protein therapy |
Its lead drug candidate, Diamyd™, is designed to reduce the need of insulin injections and prevent the destruction of beta cells. furthermore, it may allow for regeneration of beta cells in a non-autoimmune environment, thus setting the stage for a cure of the disease. Diamyd medical’s furthest developed project is Diamyd™, which is currently employed in two ongoing clinical phase ii trials of both type 2 and type 1 diabetes. Other mainstream developments include using a proprietary nerve-target delivery system to deliver gad to treat diabetes pain and neuropathy. |
http://www.diamyd.com/... |